Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Effect of Hyperglycaemia and Moxifloxacin on Cardiac Repolarisation in T2DM
NCT07014735Terminated
- Sponsor
- Richmond Pharmacology
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Trial of moxifloxacin (2 arms), sponsored by Richmond Pharmacology. Primary endpoints: Clinically significant ECG morphology and interval changes from baseline, Cardiac intervals/subintervals calculated using concentration-effect analysis at Day 3 and 4 more. Started Apr 2023; status: terminated.
02
Drugs
moxifloxacin
Beyond the preview
Go deeper on NCT07014735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014735.